EGFR-to-Src family tyrosine kinase switching in proliferating-DTP TNBC cells creates a hyperphosphorylation-dependent vulnerability to EGFR TKI
N. Chaudhary, B. S. Choudhary, A. Shivashankar, S. Manna, K. Ved, S. E. Shaikh, S. Khanna, J. Barr, J. Dani, N. Verma
Abstract
Triple-Negative Breast Cancer (TNBC) is the most aggressive type of breast malignancy, with chemotherapy as the only mainstay treatment. TNBC patients have the worst prognoses as a large fraction of them do not achieve complete pathological response post-treatment and develop drug-resistant residual disease. Molecular mechanisms that trigger proliferation in drug-resistant chemo-residual TNBC cells are poorly understood due to the lack of investigations using clinically relevant cellular models. In this study, we have established TNBC subtype-specific cellular models of proliferating drug-tolerant persister (PDTP) cells using different classes of chemotherapeutic agents that recapitulate clinical residual disease with molecular heterogeneity. Analysis of total phospho-tyrosine signals in TNBC PDTPs showed an enhanced phospho-tyrosine content compared to the parental cells (PC). Interestingly, using mass-spectrometry analysis, we identified a dramatic decrease in epidermal growth factor receptor (EGFR) expression in the PDTPs, while the presence of hyper-activated tyrosine phosphorylation of EGFR compared to PC. Further, we show that EGFR has enhanced lysosomal trafficking in PDTPs with a concomitant increase in N-Myc Downstream Regulated-1 expression that co-localizes with EGFR to mediate receptor degradation. More surprisingly, we found that reduced protein levels of EGFR are coupled with a robust increase in Src family kinases, including Lyn and Fyn kinases, that creates a hyper-phosphorylation state of EGFR-Src tyrosine kinases axis in PDTPs and mediates downstream over-activation of STAT3, AKT and MAP kinases. Moreover, paclitaxel-derived PDTPs show increased sensitivity to EGFR TKI Gefitinib and its combination with paclitaxel selectively induced cell death in PDTP-P TNBC cells and 3D spheroids by strongly downregulating phosphorylation of EGFR-Src with concomitant downregulation of Lyn and Fyn tyrosine kinases. Collectively, this study identifies a unique hyper-phosphorylation cellular state of TNBC PDTPs established by switching of EGFR-Src family tyrosine kinases creating a vulnerability to EGFR TKI.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Thioredoxin reductase 3 inhibition sensitizes triple-negative breast cancer cells to EGFR inhibitors
Prahlad V. Raninga, Göknur Giner, … Kum Kum Khanna·bioRxiv·Mar 16, 2025
- ELP-dependent expression of MCL1 promotes resistance to EGFR inhibition in triple-negative breast cancer cells
P. Cruz-Gordillo, M. E. Honeywell, … M. J. Lee·bioRxiv·Mar 29, 2020
- Contribution of Mesenchymal-like and Epithelial Cellular Subsets to Chemotherapy Resistance in Triple-Negative Breast Cancer
Ngoc Bao Vuong, Olga Y. Korolkova, … Amos M. Sakwe·bioRxiv·Nov 1, 2025
- DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma
S. K. Alam, Y. Zhang, … L. H. Hoeppner·bioRxiv·Feb 12, 2021
- On the therapeutic potential of MAPK4 in triple-negative breast cancer
F. Boudghene-Stambouli, M. Soulez, … S. Meloche·bioRxiv·Aug 24, 2022
- Single cell lineage tracing reveals subclonal dynamics of anti-EGFR therapy resistance in triple negative breast cancer.
S. Pellecchia, M. Franchini, … G. Gambardella·bioRxiv·Apr 4, 2023